{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:18:09Z","timestamp":1792721889892,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T00:00:00Z","timestamp":1778976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T00:00:00Z","timestamp":1783555200000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03207-y","type":"journal-article","created":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T05:42:37Z","timestamp":1778996557000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular, limb, and kidney effects of SGLT2 inhibitors in patients with peripheral artery disease: a systematic review and meta-analysis of randomized controlled trial data"],"prefix":"10.1186","volume":"25","author":[{"given":"Chenming","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianling","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Paneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Zelniker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabor Tamas","family":"Szabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pokreisz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno K","family":"Podesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,17]]},"reference":[{"issue":"36","key":"3207_CR1","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","volume":"45","author":"L Mazzolai","year":"2024","unstructured":"Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538\u2013700.","journal-title":"Eur Heart J"},{"issue":"8","key":"3207_CR2","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2025;151(8):e41\u2013660.","journal-title":"Circulation"},{"issue":"12","key":"3207_CR3","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","volume":"128","author":"AW Aday","year":"2021","unstructured":"Aday AW, Matsushita K. Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circ Res. 2021;128(12):1818\u201332.","journal-title":"Circ Res"},{"issue":"11","key":"3207_CR4","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jama.297.11.1197","volume":"297","author":"PG Steg","year":"2007","unstructured":"Steg PG, Bhatt DL, Wilson PW, D\u2019Agostino R, Sr., Ohman EM, R\u00f6ther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197\u2013206.","journal-title":"JAMA"},{"issue":"19","key":"3207_CR5","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1093\/eurheartj\/ehp355","volume":"30","author":"MJ Alberts","year":"2009","unstructured":"Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, R\u00f6ther J, et al. Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J. 2009;30(19):2318\u201326.","journal-title":"Eur Heart J"},{"issue":"2","key":"3207_CR6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1681\/ASN.0000000000000491","volume":"36","author":"TJ Siddiqi","year":"2025","unstructured":"Siddiqi TJ, Cherney D, Siddiqui HF, Jafar TH, Januzzi JL, Khan MS, et al. Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Kidney Outcomes across Baseline Cardiovascular-Kidney-Metabolic Conditions: A Systematic Review and Meta-Analyses. J Am Soc Nephrol. 2025;36(2):242\u201355.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"3207_CR7","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43044-025-00623-5","volume":"77","author":"HF Siddiqui","year":"2025","unstructured":"Siddiqui HF, Khan AB, Nasir MM, Hashmi T, Siddiqui AF, Asim H, et al. Safety and efficacy of SGLT2 inhibitors in heart failure patients with ischemic and non-ischemic etiologies: a systematic review and meta-analyses. Egypt Heart J. 2025;77(1):32.","journal-title":"Egypt Heart J"},{"key":"3207_CR8","doi-asserted-by":"publisher","first-page":"1008922","DOI":"10.3389\/fcvm.2022.1008922","volume":"9","author":"L Scisciola","year":"2022","unstructured":"Scisciola L, Cataldo V, Taktaz F, Fontanella RA, Pesapane A, Ghosh P, et al. Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front Cardiovasc Med. 2022;9:1008922.","journal-title":"Front Cardiovasc Med"},{"issue":"8","key":"3207_CR9","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1161\/HYPERTENSIONAHA.122.19586","volume":"79","author":"P Mone","year":"2022","unstructured":"Mone P, Varzideh F, Jankauskas SS, Pansini A, Lombardi A, Frullone S, et al. SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension. 2022;79(8):1633\u201343.","journal-title":"Hypertension"},{"issue":"42","key":"3207_CR10","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1093\/eurheartj\/ehw110","volume":"37","author":"N Marx","year":"2016","unstructured":"Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. 2016;37(42):3192\u2013200.","journal-title":"Eur Heart J"},{"issue":"21","key":"3207_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"41","key":"3207_CR12","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","volume":"43","author":"D von Lewinski","year":"2022","unstructured":"von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421\u201332.","journal-title":"Eur Heart J"},{"issue":"37","key":"3207_CR13","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"6","key":"3207_CR14","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1111\/dom.14671","volume":"24","author":"JY Barraclough","year":"2022","unstructured":"Barraclough JY, Yu J, Figtree GA, Perkovic V, Heerspink HJL, Neuen BL, et al. Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2022;24(6):1072\u201383.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"3207_CR15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","volume":"142","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Wiviott SD, Zelniker TA, Mosenzon O, Bhatt DL, Leiter LA, et al. Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. Circulation. 2020;142(8):734\u201347.","journal-title":"Circulation"},{"issue":"24","key":"3207_CR16","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1093\/eurheartj\/ehad276","volume":"44","author":"JH Butt","year":"2023","unstructured":"Butt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, et al. Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. Eur Heart J. 2023;44(24):2170\u201383.","journal-title":"Eur Heart J"},{"issue":"7","key":"3207_CR17","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/ATVBAHA.123.319156","volume":"43","author":"S Verma","year":"2023","unstructured":"Verma S, Dhingra NK, Bonaca MP, Butler J, Anker SD, Ferreira JP, et al. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled. Arterioscler Thromb Vasc Biol. 2023;43(7):1334\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"3207_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","volume":"137","author":"S Verma","year":"2018","unstructured":"Verma S, Mazer CD, Al-Omran M, Inzucchi SE, Fitchett D, Hehnke U, et al. Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. Circulation. 2018;137(4):405\u20137.","journal-title":"Circulation"},{"key":"3207_CR19","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.","journal-title":"BMJ"},{"key":"3207_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"key":"3207_CR21","doi-asserted-by":"publisher","first-page":"c117","DOI":"10.1136\/bmj.c117","volume":"340","author":"X Sun","year":"2010","unstructured":"Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117.","journal-title":"BMJ"},{"issue":"5","key":"3207_CR22","first-page":"560","volume":"38","author":"BL Abramson","year":"2022","unstructured":"Abramson BL, Al-Omran M, Anand SS, Albalawi Z, Coutinho T, de Mestral C, et al. Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. Can J Cardiol. 2022;38(5):560\u201387.","journal-title":"Can J Cardiol"},{"issue":"24","key":"3207_CR23","doi-asserted-by":"publisher","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","volume":"149","author":"HL Gornik","year":"2024","unstructured":"Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313\u2013410.","journal-title":"Circulation"},{"issue":"7","key":"3207_CR24","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"12","key":"3207_CR25","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1111\/dom.14159","volume":"22","author":"CY Huang","year":"2020","unstructured":"Huang CY, Lee JK. Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: A trial-level meta-analysis including 51 713 individuals. Diabetes Obes Metab. 2020;22(12):2348\u201355.","journal-title":"Diabetes Obes Metab"},{"issue":"3\u20134","key":"3207_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000520903","volume":"107","author":"RM See","year":"2022","unstructured":"See RM, Teo YN, Teo YH, Syn NL, Yip ASY, Leong S, et al. Effects of Sodium-Glucose Cotransporter 2 on Amputation Events: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials. Pharmacology. 2022;107(3\u20134):123\u201330.","journal-title":"Pharmacology"},{"issue":"11","key":"3207_CR27","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1111\/dom.15901","volume":"26","author":"L Geng","year":"2024","unstructured":"Geng L, Sun B, Chen Y. A meta-analysis of randomized controlled studies examining the effects of sodium-glucose co-transporter-2 inhibitors on peripheral artery disease and risk of amputations. Diabetes Obes Metab. 2024;26(11):5376\u201389.","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"3207_CR28","doi-asserted-by":"publisher","first-page":"e840","DOI":"10.1161\/CIR.0000000000000664","volume":"139","author":"J Rangaswami","year":"2019","unstructured":"Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, et al. Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. Circulation. 2019;139(16):e840\u201378.","journal-title":"Circulation"},{"issue":"5","key":"3207_CR29","doi-asserted-by":"publisher","first-page":"sfaf089","DOI":"10.1093\/ckj\/sfaf089","volume":"18","author":"S Huish","year":"2025","unstructured":"Huish S, Nawaz S, Bellasi A, Diaz-Tocados JM, Haarhaus M, Sinha S. Clinical management of peripheral arterial disease in chronic kidney disease-a comprehensive review from the European Renal Association CKD-MBD Working Group. Clin Kidney J. 2025;18(5):sfaf089.","journal-title":"Clin Kidney J"},{"issue":"11","key":"3207_CR30","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/j.jacc.2021.06.049","volume":"78","author":"P Lanzer","year":"2021","unstructured":"Lanzer P, Hannan FM, Lanzer JD, Janzen J, Raggi P, Furniss D, et al. Medial Arterial Calcification: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021;78(11):1145\u201365.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3207_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/15347346231211959","volume":"23","author":"A Rerkasem","year":"2024","unstructured":"Rerkasem A, Mangklabruks A, Buranapin S, Sony K, Inpankaew N, Rerkasem R, et al. Chronic Kidney Disease Predicts Adverse Major Cardiovascular Events and Adverse Limb Events in Patients With Diabetes and Peripheral Arterial Disease. Int J Low Extrem Wounds. 2024;23(1):19\u201326.","journal-title":"Int J Low Extrem Wounds"},{"issue":"1","key":"3207_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.12.027","volume":"94","author":"HJL Heerspink","year":"2018","unstructured":"Heerspink HJL, Kosiborod M, Inzucchi SE, Cherney DZI. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. Kidney Int. 2018;94(1):26\u201339.","journal-title":"Kidney Int"},{"issue":"4","key":"3207_CR33","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(4):422\u201334.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3207_CR34","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","volume":"134","author":"HJ Heerspink","year":"2016","unstructured":"Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752\u201372.","journal-title":"Circulation"},{"issue":"15","key":"3207_CR35","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"key":"3207_CR36","first-page":"100291","volume":"28","author":"M Bethel","year":"2023","unstructured":"Bethel M, Annex BH. Peripheral arterial disease: A small and large vessel problem. Am Heart J Plus. 2023;28:100291.","journal-title":"Am Heart J Plus"},{"issue":"12","key":"3207_CR37","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","volume":"128","author":"MP Bonaca","year":"2021","unstructured":"Bonaca MP, Hamburg NM, Creager MA. Contemporary Medical Management of Peripheral Artery Disease. Circ Res. 2021;128(12):1868\u201384.","journal-title":"Circ Res"},{"key":"3207_CR38","doi-asserted-by":"publisher","first-page":"1054576","DOI":"10.3389\/fcvm.2022.1054576","volume":"9","author":"MM Kavurma","year":"2022","unstructured":"Kavurma MM, Bursill C, Stanley CP, Passam F, Cartland SP, Patel S, et al. Endothelial cell dysfunction: Implications for the pathogenesis of peripheral artery disease. Front Cardiovasc Med. 2022;9:1054576.","journal-title":"Front Cardiovasc Med"},{"issue":"5","key":"3207_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1093\/cvr\/cvae047","volume":"120","author":"A Preda","year":"2024","unstructured":"Preda A, Montecucco F, Carbone F, Camici GG, L\u00fcscher TF, Kraler S, et al. SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits. Cardiovasc Res. 2024;120(5):443\u201360.","journal-title":"Cardiovasc Res"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03207-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03207-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03207-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T04:14:09Z","timestamp":1783570449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03207-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,17]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3207"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03207-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,17]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author F.P. serves as an Associate Editor of this journal. Author T.A.Z. reports research grants from the Austrian Science Funds and Boehringer Ingelheim; honoraria for serving on advisory boards from Bayer AG, Boehringer Ingelheim, and Eli Lilly and Company; personal fees from Alkem Lab. Ltd, AstraZeneca, Bayer AG, Boehringer Ingelheim, Eli Lilly and Company, NovoNordisk, and Sun Pharmaceutical Industries. All these funding sources and disclosures are unrelated to the present study. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}